OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.05 USD
+0.06 (2.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.19 +0.14 (4.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCX 3.05 +0.06(2.01%)
Will OCX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for OCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCX
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
OCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
3 Medical Services Stocks to Buy Amid Industry Challenges
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates
Other News for OCX
OncoCyte Secures Funding Through Private Share Sale
Oncocyte gains 6% on $10.2M private placement
PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
Oncocyte?s VitaGraft? Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript